No evidence for cardiotoxicity of miltefosine
- PMID: 35654652
- PMCID: PMC9263634
- DOI: 10.1016/j.abd.2022.03.002
No evidence for cardiotoxicity of miltefosine
Comment in
-
No evidence for cardiotoxicity of miltefosine - Reply.An Bras Dermatol. 2022 Jul-Aug;97(4):549-550. doi: 10.1016/j.abd.2022.03.001. Epub 2022 Jun 3. An Bras Dermatol. 2022. PMID: 35667981 Free PMC article. No abstract available.
Comment on
-
Comparison of cardiotoxicity between N-methyl-glucamine and miltefosine in the treatment of American cutaneous leishmaniasis.An Bras Dermatol. 2021 Jul-Aug;96(4):502-504. doi: 10.1016/j.abd.2021.02.002. Epub 2021 May 15. An Bras Dermatol. 2021. PMID: 34001400 Free PMC article. No abstract available.
References
-
- Sundar S., Jha T.K., Thakur C.P., Engel J., Sindermann H., Fischer C., et al. Oral miltefosine for Indian visceral leishmaniasis. N Engl J Med. 2002;347:1739–1746. - PubMed
-
- Dorlo T.P.C., Balasegaram M., Beijnen J.H., de Vries P.J. Miltefosine: a review of its pharmacology and therapeutic efficacy in the treatment of leishmaniasis. J Antimicrob Chemother. 2012;67:2576–2597. - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources